IN THE NEWS
Abnewswire, Janurary 2017
ATRAPOS THERAPEUTICS is developing targeted immunomodulatory therapeutics for management of diseases with inappropriate immune responses. The company is targeting STAT6 which is an important player in the pathway involved in TH2 immune cells involved in several disease settings. The molecule has demonstrated encouraging activity in animal models of allergic asthma and is currently being evaluated in other therapeutic settings.
STAT6 is a messenger molecule found in T helper lymphocytes (Th2 cells, a type of immune cell). In response to cytokines and growth factors, STAT family members are
phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein plays a central role in exerting IL4 mediated biological responses. Th2 has been described as playing a central role in the immune response in several diseases, like asthma and idiopathic pulmonary fibrosis. Although STAT6 has been identified as an attractive therapeutic target, developing an inhibitor has been challenging due to the inability of charged inhibitory molecules to traverse the plasma membrane. The company’s novel molecule is delivered as a pro-drug that is converted to an active form within the cytoplasm then proceeds to bind to the STAT6 molecule and prevents signal transduction.
The novel drug molecule has demonstrated encouraging activity in animal models of allergic asthma and pulmonary fibrosis, and is currently being evaluated in other therapeutic settings.